Key points are not available for this paper at this time.
Abstract Therapeutic innate immune stimulation within the tumor microenvironment can potentiate endogenous antitumor T cell immunity. DNase 3’-repair exonuclease 1 (TREX1) is essential for cellular DNA disposal which prevents autoimmunity ensuing from cGAS/STING activation by endogenous DNA. Optimal strategies to therapeutically leverage cGAS/STING signalling for cancer therapy are highly sought after. TREX1-deficient tumor cells elicit enhanced protective immunity in syngeneic models. Here we show that induced inactivation of the Trex1 gene in (non-malignant) host cells is well tolerated and yields improved type I IFN- and T cell-dependent control of established TREX1-competent tumors with selective immune cell infiltration of tumor, but not other tissues. Intra-tumoral T cell proliferation and numbers of effector and effector-like ‘exhausted’ cells massively increased, enabling complete rejection in synergy with checkpoint inhibition. We conclude that systemic TREX1 inhibition is a promising approach to boost anti-tumor immunity, that can overcome immune evasion by cancer cell- intrinsic cGAS/STING inactivation.
Marinković et al. (Mon,) studied this question.